| PQR309 is a novel dual PI3K/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy C Tarantelli, E Gaudio, AJ Arribas, I Kwee, P Hillmann, A Rinaldi, ... Clinical Cancer Research 24 (1), 120-129, 2018 | 108 | 2018 |
| Marine anticancer agents: An overview with a particular focus on their chemical classes M Barreca, V Spanò, A Montalbano, M Cueto, AR Díaz Marrero, I Deniz, ... Marine drugs 18 (12), 619, 2020 | 83 | 2020 |
| Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734 F Spriano, E Gaudio, L Cascione, C Tarantelli, F Melle, G Motta, V Priebe, ... Blood advances 4 (17), 4124-4135, 2020 | 53 | 2020 |
| Targeting BET bromodomain proteins in cancer: The example of lymphomas F Spriano, A Stathis, F Bertoni Pharmacology & therapeutics 215, 107631, 2020 | 52 | 2020 |
| The ETS inhibitors YK-4-279 and TK-216 are novel antilymphoma agents F Spriano, EYL Chung, E Gaudio, C Tarantelli, L Cascione, S Napoli, ... Clinical Cancer Research 25 (16), 5167-5176, 2019 | 43 | 2019 |
| Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma E Bernasconi, E Gaudio, P Lejeune, C Tarantelli, L Cascione, I Kwee, ... British journal of haematology 178 (6), 936-948, 2017 | 43 | 2017 |
| DNA damage response inhibitor combinations exert synergistic antitumor activity in aggressive B-cell lymphomas V Restelli, M Lupi, R Chilà, M Vagni, C Tarantelli, F Spriano, E Gaudio, ... Molecular cancer therapeutics 18 (7), 1255-1264, 2019 | 37 | 2019 |
| Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer T Bernasocchi, G El Tekle, M Bolis, A Mutti, A Vallerga, LP Brandt, ... Nature communications 12 (1), 734, 2021 | 35 | 2021 |
| Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models E Gaudio, C Tarantelli, F Spriano, F Guidetti, G Sartori, R Bordone, ... Haematologica 105 (11), 2584, 2020 | 31 | 2020 |
| Copanlisib synergizes with conventional and targeted agents including venetoclax in B-and T-cell lymphoma models C Tarantelli, M Lange, E Gaudio, L Cascione, F Spriano, I Kwee, ... Blood advances 4 (5), 819-829, 2020 | 31 | 2020 |
| The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models SW Hicks, C Tarantelli, A Wilhem, E Gaudio, M Li, AJ Arribas, F Spriano, ... haematologica 104 (8), 1633, 2019 | 31 | 2019 |
| Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study … F Ricci, M Fratelli, F Guffanti, L Porcu, F Spriano, T Dell’Anna, R Fruscio, ... Oncotarget 8 (5), 7441, 2017 | 29 | 2017 |
| BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance C Tarantelli, E Bernasconi, E Gaudio, L Cascione, V Restelli, AJ Arribas, ... ESMO open 3 (6), e000387, 2018 | 28 | 2018 |
| Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity M Barreca, V Spano, MV Raimondi, C Tarantelli, F Spriano, F Bertoni, ... European Journal of Medicinal Chemistry Reports 1, 100004, 2021 | 25 | 2021 |
| Identification of a new family of pyrazolo [3, 4-d] pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B-and T-lymphoma cell lines AL Fallacara, R Passannanti, M Mori, G Iovenitti, F Musumeci, C Greco, ... European journal of medicinal chemistry 181, 111545, 2019 | 19 | 2019 |
| Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP‐319 in pre‐clinical models of aggressive lymphomas F Spriano, C Tarantelli, E Gaudio, MM Gerlach, V Priebe, L Cascione, ... British journal of haematology 187 (5), 595-601, 2019 | 16 | 2019 |
| The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents C Tarantelli, L Zhang, E Curti, E Gaudio, F Spriano, V Priebe, L Cascione, ... Haematologica 104 (7), e307, 2019 | 16 | 2019 |
| The novel TORC1/2 kinase inhibitor PQR620 has anti-tumor activity in lymphomas as a single agent and in combination with venetoclax C Tarantelli, E Gaudio, P Hillmann, F Spriano, G Sartori, L Aresu, ... Cancers 11 (6), 775, 2019 | 14 | 2019 |
| Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis AJ Arribas, S Napoli, L Cascione, G Sartori, L Barnabei, E Gaudio, ... Haematologica 107 (11), 2685, 2022 | 11 | 2022 |
| Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences M Barreca, N Lang, C Tarantelli, F Spriano, P Barraja, F Bertoni Exploration of Targeted Anti-tumor Therapy 3 (6), 763, 2022 | 11 | 2022 |
